PAGB response to link between use of PPIs and H2-receptor antagonists in pregnancy and childhood asthma

Published on: 9th January 2017

img

Research from the University of Edinburgh has suggested that children born to mothers who have taken prescribed heartburn medication (PPIs and H2-receptor antagonists) during pregnancy, may have a greater risk of developing asthma.

John Smith, PAGB Chief Executive, comments:

“This study focused specifically on prescribed PPIs and H2-receptor antagonists for heartburn and not those that are available over-the-counter (OTC). Heartburn medication available OTC is only intended to be used for a short-term period and is not recommended for continuous use.

“The authors of this study also note that the association between these drugs and asthma could be caused by a separate factor and further research is needed to determine whether they have any effect on children’s health.

“The NHS advice is that several indigestion medicines are appropriately safe to use during pregnancy and we would advise pregnant women to always speak to their pharmacist, midwife or GP if they have any questions or concerns.”

PAGB response to link between use of PPIs and H2-receptor antagonists in pregnancy and childhood asthma

 

Share: